HUE026480T2 - Stromális õssejtek - Google Patents

Stromális õssejtek Download PDF

Info

Publication number
HUE026480T2
HUE026480T2 HUE13707295A HUE13707295A HUE026480T2 HU E026480 T2 HUE026480 T2 HU E026480T2 HU E13707295 A HUE13707295 A HU E13707295A HU E13707295 A HUE13707295 A HU E13707295A HU E026480 T2 HUE026480 T2 HU E026480T2
Authority
HU
Hungary
Prior art keywords
cells
cell
human
sdc2
population
Prior art date
Application number
HUE13707295A
Other languages
English (en)
Inventor
Stephen Joseph Elliman
Original Assignee
Orbsen Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbsen Therapeutics Ltd filed Critical Orbsen Therapeutics Ltd
Publication of HUE026480T2 publication Critical patent/HUE026480T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Claims (9)

  1. Ezisbadalnû îgéay pontok
    1, Emlős stromaiis őssejtek popnMciqja, ahol a sejtek közűi 36% vagy több szinookán-2· pozitív,
  2. 2. Sejtpopuládő az I, igénypont szén ni.. ahol a sejtek egér·:, patkány·', 16" vagy hnmán-sejtek, 3» Sejtpopuláció a 2, igénypont szerint, ahol a sejtek humán-sejtek.
  3. 4, Sejtpopuláció as 1,-fol dug igénypontok bármelyike szedni, ahol a sejtek közöl 40 6 vagy több szludekán-2'-poziifv, S> Sejtpopuláció az 1 .-töl 4,-ig igénypontok bármelyike szerint, ahol a sejtek közül 50% vagy több szindeldmfo-pozbfv.
  4. 6, Sejtpopuláció as L~tői 5.cg igénypontok bármelyike szedni, ahol a sejtek kösd 75% vagy több sz.moekán--2-po/üiv.
  5. 7, Eljárás egy stromab« őssejt izolálására, amely magában: foglalja egy sejt izolálását emlős sejtek egy vegyes populációjából a szieöekán-2 expresszfoju alapján. b. Eljárás a 7, Igénypont szedni humán-sejtek izolálására,
  6. 9, Eljárás a 7> igénypont szerda egér··, patkány- vagy iő-sejtek izolálására.
  7. 16, Eljárás a 7,-tol dug igénypontok bármelyike szedni álról az emlős sqjtek vegyes popaládőja egy forrásból vau kinyerve, amely a kővetkezők kösüi van választva: csontvelő, zsírszövet, vázizomzat, endometdmn, méhhpéay (piacénla), köldökzsinörvér, .köldökzsinór, Wbarfoa-kocsonya és píudpotens sejtekből származó sejtek, l.L Eljárás a 10. igénypont szerint oszteogén és angiopoedkus: (angolul: , angdpoieded sejtek izolálására. 12, kijárás a 7,.-tol 11,dg igénypontok bármelyike szerint stromális sejtek izolálására, amely továbbá magában foglalja a lépést, amely egy sejtpopuláció származtatásából áll azokból az: izolált sejtekbők" ;...........................................................................................................................................................
    13, Eljárás egy kionálls sejtpopuláció kinyerésére, amely magában foglalja egy egyedi sejt izolálását a 7.-től 11,-tg igénypomok bármely-ke szerinti eljárás szerint; és egy klonális sejtpopuláció származtatását az egyedi sejtből. 14 Eljárás szövet kinyerésére, amely magában foglalja sejtek kinyerését a /.-tői 13.-ig igénypontok bármelyike szerint, és szövet kinyerését azokból
    15, Eljárás a 14. igény pont szerint, ahol a szövet csont, M. Eljárás a 14, igénypont szerint, ahol a: szövet porc. .17> Eljárás a 14. Igénypont szerint, ahol a szövet in, IS, Vizsgálat, amely magában foglalja az l.-tol 6.-ig igénypontok bármelyike szerinti sejtek alkalmazását
  8. 19, Gyógyászati készítmény egy betegség vagy rendellenesség kezelésére egy állatnák például egy embernél., amely tartalmaz sejteket az E-tol ő,-ig igénypontok bármelyike szerint, 2fk Készítmény a 19. igénypont szerint, amely tartalmaz sóöldafot vagy foszfáttal puffotok söoldatd és opdonállsan továbbá tartalmaz egyet vagy többet a következők közül: dimed I-szid fodd, humán szérum albnnrin, hiainronsav és kollagén.
  9. 21, Sejtek az 1,-foi 6.-ig igénypontok bármelyiké szentit alkalmazás céljából egy állat, például egy ember, egy betegségének vagy rendellenességének a kezelésére.
HUE13707295A 2012-02-10 2013-02-11 Stromális õssejtek HUE026480T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1202319.8A GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells

Publications (1)

Publication Number Publication Date
HUE026480T2 true HUE026480T2 (hu) 2016-06-28

Family

ID=45929927

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13707295A HUE026480T2 (hu) 2012-02-10 2013-02-11 Stromális õssejtek

Country Status (22)

Country Link
US (9) US11230700B2 (hu)
EP (4) EP4257203A3 (hu)
JP (1) JP5829765B2 (hu)
KR (1) KR102124837B1 (hu)
CN (1) CN104302763B (hu)
AU (1) AU2013217870B2 (hu)
BR (1) BR112014019277A8 (hu)
CA (1) CA2863821C (hu)
CY (1) CY1116365T1 (hu)
DK (1) DK2758523T3 (hu)
ES (3) ES2539186T3 (hu)
GB (1) GB201202319D0 (hu)
HR (1) HRP20150594T1 (hu)
HU (1) HUE026480T2 (hu)
IN (1) IN2014KN01777A (hu)
PL (1) PL2758523T3 (hu)
PT (1) PT2758523E (hu)
RS (1) RS54073B1 (hu)
RU (1) RU2636551C2 (hu)
SI (1) SI2758523T1 (hu)
SM (1) SMT201500147B (hu)
WO (1) WO2013117761A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CN105324391A (zh) 2013-04-16 2016-02-10 奥尔布森治疗学有限公司 多配体蛋白聚糖-2的医学用途
WO2015121380A1 (en) 2014-02-12 2015-08-20 National University Of Ireland, Galway Selection and use of stem cells
KR101690872B1 (ko) 2014-08-19 2016-12-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
US9716660B2 (en) * 2014-12-11 2017-07-25 Intel Corporation Hierarchical enforcement of service flow quotas
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−２のモジュレーターとその使用
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
US20210154235A1 (en) * 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
US11268067B2 (en) 2017-07-14 2022-03-08 Orbsen Therapeutics Limited Methods of isolation and use of CD39 stromal stem cells
WO2022179518A1 (en) * 2021-02-25 2022-09-01 Rosas Ivan O Anti-fibrotic peptides and uses thereof
CN116334214A (zh) * 2023-04-04 2023-06-27 暨南大学附属第一医院（广州华侨医院） 一种用于急性心肌梗死和稳定性心绞痛鉴别的生物标志物的ceRNA调控网络及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012403A (en) 1911-01-23 1911-12-19 Thomas W Mcneill Smoke-indicator.
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5726058A (en) 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
WO1997034605A1 (en) 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
EP1062321B1 (en) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
CA2328524A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
EP1276486B2 (en) 2000-04-25 2014-03-05 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
US7442390B2 (en) * 2000-06-05 2008-10-28 University Of South Florida Method for enhancing engraftment of cells using mesenchymal progenitor cells
WO2002087609A1 (en) 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
AU2003214857A1 (en) 2002-01-18 2003-09-02 Regents Of The University Of Minnesota Syndecans and angiogenesis
AU2003236557B2 (en) 2002-06-27 2009-10-01 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
JP4672370B2 (ja) * 2002-12-05 2011-04-20 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
AU2005227295A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1789534B1 (en) * 2004-08-16 2014-08-06 CellResearch Corporation Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2007122823A1 (ja) 2006-04-20 2007-11-01 Jichi Medical University ベクター産生型腫瘍標的細胞
US20070264239A1 (en) 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
WO2008085229A2 (en) 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR100883565B1 (ko) 2007-02-14 2009-02-13 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
CA2693144A1 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CN101835889B (zh) 2007-10-17 2013-07-17 特克赛尔公司 Tr1细胞、间充质干细胞和其用途
RU2010136966A (ru) * 2008-02-04 2012-03-20 Байпар Сайенсиз, Инк. (Us) Способы диагностики и лечения заболеваний, опосредованных parp
US20090220588A1 (en) 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
WO2010065239A1 (en) 2008-12-05 2010-06-10 Wake Forest University Health Sciences Stem cells from urine and methods for using the same
KR20100106744A (ko) 2009-03-24 2010-10-04 이화여자대학교 산학협력단 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물
CN102695517B (zh) 2009-04-13 2015-01-28 埃普塞斯有限责任两合公司 经改造的间充质干细胞和用其治疗肿瘤的方法
KR101301262B1 (ko) 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
KR101622650B1 (ko) 2009-12-31 2016-06-01 엘지디스플레이 주식회사 액정 전계 렌즈 및 이를 이용한 입체 표시 장치
US9394521B2 (en) 2010-03-10 2016-07-19 Two Cells Co., Ltd. Cell preparation containing mesenchymal stem cells, and method for producing same
WO2011153458A2 (en) 2010-06-03 2011-12-08 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
ES2667532T3 (es) 2010-06-18 2018-05-11 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neogénesis del folículo piloso
KR101309910B1 (ko) 2010-08-06 2013-09-17 이화여자대학교 산학협력단 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편
KR101317507B1 (ko) 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
US10935542B2 (en) * 2010-12-22 2021-03-02 The Administrators Of The Tulane Educational Fund Office Of Technology Transfer And Intellectual Property Development Method for identification and culture of multipotent mesenchymal stem cells with high proliferation potential
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
KR101145406B1 (ko) * 2011-07-06 2012-05-15 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
US20150125950A1 (en) 2012-05-18 2015-05-07 Agency For Science, Technology And Research (A*Sta (A*Star) Umbilical cord mesenchymal stem cell exosomes
SG11201508433TA (en) 2013-04-12 2015-11-27 Andaloussi Samir El Therapeutic delivery vesicles
CN105324391A (zh) 2013-04-16 2016-02-10 奥尔布森治疗学有限公司 多配体蛋白聚糖-2的医学用途
WO2015038075A1 (en) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
ES2769778T3 (es) 2013-12-13 2020-06-29 Swedish Stromabio Ab Composiciones inmunomoduladoras
EP3656387A3 (en) 2014-08-18 2020-07-01 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
GB201418562D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−２のモジュレーターとその使用
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
EP3848373A1 (en) 2016-02-19 2021-07-14 Phoenix Molecular Designs N-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
US20210154235A1 (en) 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
US11268067B2 (en) 2017-07-14 2022-03-08 Orbsen Therapeutics Limited Methods of isolation and use of CD39 stromal stem cells
WO2020035741A2 (en) 2018-07-05 2020-02-20 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof
US20220288129A1 (en) 2019-08-23 2022-09-15 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use

Also Published As

Publication number Publication date
US20200078413A1 (en) 2020-03-12
BR112014019277A8 (pt) 2017-07-11
US11434471B2 (en) 2022-09-06
JP2015509360A (ja) 2015-03-30
EP2758523B1 (en) 2015-03-11
US20150037292A1 (en) 2015-02-05
RU2636551C2 (ru) 2017-11-23
CY1116365T1 (el) 2017-02-08
CA2863821A1 (en) 2013-08-15
PT2758523E (pt) 2015-07-21
US20220090019A1 (en) 2022-03-24
SMT201500147B (it) 2015-09-07
US20220112466A1 (en) 2022-04-14
EP2902482A1 (en) 2015-08-05
RS54073B1 (en) 2015-10-30
ES2959833T3 (es) 2024-02-28
ES2697780T3 (es) 2019-01-28
KR20140143363A (ko) 2014-12-16
PL2758523T3 (pl) 2015-08-31
GB201202319D0 (en) 2012-03-28
US20230313142A1 (en) 2023-10-05
CA2863821C (en) 2023-09-19
US11884936B2 (en) 2024-01-30
US11142747B2 (en) 2021-10-12
EP3492584A1 (en) 2019-06-05
ES2539186T3 (es) 2015-06-26
US20160215265A1 (en) 2016-07-28
US10920197B2 (en) 2021-02-16
US20230323307A1 (en) 2023-10-12
WO2013117761A1 (en) 2013-08-15
US11952589B2 (en) 2024-04-09
EP4257203A3 (en) 2024-05-15
HRP20150594T1 (hr) 2015-07-17
EP2758523A1 (en) 2014-07-30
US20230332106A1 (en) 2023-10-19
AU2013217870B2 (en) 2018-11-08
EP2902482B1 (en) 2018-09-19
US11926848B2 (en) 2024-03-12
US11952590B2 (en) 2024-04-09
US11230700B2 (en) 2022-01-25
RU2014136711A (ru) 2016-03-27
AU2013217870A1 (en) 2014-09-11
CN104302763A (zh) 2015-01-21
US10907131B2 (en) 2021-02-02
KR102124837B1 (ko) 2020-06-22
EP3492584B1 (en) 2023-07-19
SI2758523T1 (sl) 2015-10-30
JP5829765B2 (ja) 2015-12-09
IN2014KN01777A (hu) 2015-10-23
CN104302763B (zh) 2017-08-29
US20180298341A1 (en) 2018-10-18
EP4257203A2 (en) 2023-10-11
DK2758523T3 (da) 2015-06-22
BR112014019277A2 (hu) 2017-06-20

Similar Documents

Publication Publication Date Title
US11926848B2 (en) Stromal stem cells
CA2426987C (en) Human cord blood derived unrestricted somatic stem cells (ussc)
Invernici et al. Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia
JP2017522029A (ja) プールした複数の骨髄ドナーの単核細胞からの間葉系間質細胞バンクの生成
US20150093447A1 (en) Stem cell identification and purification method
KR101756429B1 (ko) 클로날 중간엽 줄기세포를 포함하는, 발기부전 예방 또는 치료용 약학적 조성물